Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VistaGen Therapeutics has received around $500,000 from the US National Institutes of Health (NIH) to accelerate development of novel and safer approaches to produce patient-specific induced pluripotent stem (iPS) cells for regenerative medicine, drug discovery and drug rescue.
Subscribe to our email newsletter
VistaGen said that the NIH grant will support further development of patient-specific iPS cell programming processes by NuPotential, as well as VistaGen’s differentiation protocols and processes focused on the validation and use of the iPS cells for regenerative medicine applications and in clinically-relevant biological assays for small molecule drug discovery and drug rescue.
VistaGen CEO Shawn Singh said that the iPS cells produced through NuPotential’s safer reprogramming processes are expected to offer them many advantages in drug discovery and drug rescue applications of our Human Clinical Trials in a Test Tube platform.